Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9.

Article  PubMed  CAS  Google Scholar 

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.

Article  PubMed  CAS  Google Scholar 

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–209.

Article  PubMed  Google Scholar 

Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–7.

Article  PubMed  Google Scholar 

Weber BN, Giles JT, Liao KP. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat Rev Rheumatol. 2023;19(7):417–28.

Article  PubMed  PubMed Central  Google Scholar 

Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020;16(7):361–79.

Article  PubMed  Google Scholar 

Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel P, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48–54.

Article  PubMed  CAS  Google Scholar 

Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4(2):e001588.

Article  PubMed  PubMed Central  Google Scholar 

Robertson J, Porter D, Sattar N, Packard CJ, Caslake M, McInnes I, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017;76(11):1949–52.

Article  PubMed  CAS  Google Scholar 

Crowson CS, Matteson EL, Roger VL, Therneau TM, Gabriel SE. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110(3):420–4.

Article  PubMed  PubMed Central  Google Scholar 

Garshick M, Underberg JA. The use of primary prevention statin therapy in those predisposed to atherosclerosis. Curr Atheroscler Rep. 2017;19(12):48.

Article  PubMed  Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376–414.

Article  PubMed  PubMed Central  Google Scholar 

Ljung L, Ueda P, Liao KP, Greenberg JD, Etzel CJ, Solomon DH, et al. Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation. RMD Open. 2018;4(2):e000771.

Article  PubMed  PubMed Central  Google Scholar 

Wahlin B, Innala L, Magnusson S, Moller B, Smedby T, Rantapaa-Dahlqvist S, et al. Performance of the expanded cardiovascular risk prediction score for rheumatoid arthritis is not superior to the ACC/AHA risk calculator. J Rheumatol. 2019;46(2):130–7.

Article  PubMed  Google Scholar 

Ren C, Li M. The efficacy of statins in the treatment of rheumatoid arthritis: A systematic review and meta-analysis. Medicine (Baltimore). 2023;102(37):e35088.

Article  PubMed  CAS  Google Scholar 

Schoenfeld SR, Lu L, Rai SK, Seeger JD, Zhang Y, Choi HK. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis. 2016;75(7):1315–20.

Article  PubMed  CAS  Google Scholar 

Chhibber A, Hansen S, Biskupiak J. Statin use and mortality in rheumatoid arthritis: an incident user cohort study. J Manag Care Spec Pharm. 2021;27(3):296–305.

PubMed  Google Scholar 

Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM, et al. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1437–49.

Article  PubMed  PubMed Central  CAS  Google Scholar 

McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4):694–702.

Article  PubMed  CAS  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316–26.

Article  PubMed  CAS  Google Scholar 

Giles JT, Charles-Schoeman C, Buch M, Dougados M, Zoltan S, Mikuls T, et al. Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis. ACR Converg. 2024. 2024.

Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, Boy M, Geier J, Luo Z, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016;46(1):71–80.

Article  PubMed  CAS  Google Scholar 

Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum. 2013;43(1):77–95.

Article  PubMed  Google Scholar 

Durcan L, Winegar DA, Connelly MA, Otvos JD, Magder LS, Petri M. Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy. J Rheumatol. 2016;43(4):745–50.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sivakumaran J, Harvey P, Omar A, Tayer-Shifman O, Urowitz MB, Gladman DD, et al. Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med. 2021;8(1):e000448.

Article  PubMed  PubMed Central  Google Scholar 

Choi MY, Guan H, Yoshida K, Paudel M, Kargere BA, Li D, et al. Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2024;67:152468.

Article  PubMed  Google Scholar 

van Leuven SI, Mendez-Fernandez YV, Stroes ES, Tak PP, Major AS. Statin therapy in lupus-mediated atherogenesis: two birds with one stone? Ann Rheum Dis. 2011;70(2):245–8.

Article  PubMed  Google Scholar 

Artola RT, Mihos CG, Santana O. Effects of statin therapy in patients with systemic lupus erythematosus. South Med J. 2016;109(11):705–11.

Article  PubMed  CAS  Google Scholar 

Yu HH, Chen PC, Yang YH, Wang LC, Lee JH, Lin YT, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. Atherosclerosis. 2015;243(1):11–8.

Article  PubMed  CAS  Google Scholar 

Papazoglou N, Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology (Oxford). 2024;63(1):50–7.

Article  PubMed  CAS  Google Scholar 

Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012;64(1):285–96.

Article  PubMed  PubMed Central